Novartis presented the histology data of iscalimab in the patients who underwent kidney transplantation. The study is showing the durability and long-term benefits with iscalimab in the patients who underwent kidney transplantation.
Iscalimab is a monoclonal antibody. Mechanism of action includes inhibiting cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types
The data was presented at the American Transplant Congress. The efficacy of iscalimab compared with tacrolimus by using chronic allograft damage index, 60% of patients shown normal histological data in the iscalimab arm compared to none on tacrolimus arm.
Comments